QTc prolongation and mortality in SARS-2-CoV-infected patients treated with azithromycin and hydroxychloroquine

Enrico Baldi^{1

2}, Roberto Rordorf¹, Lucrezia Masiello^{1

2}, Sabato D'Amore^{1

2}, Stefano Ghio³, Elena Maria Seminari⁴, Federica Melazzini⁵, Elia Fraolini⁶, Stefano Perlini^{7

5}, Guido Tavazzi^{8

9}, Alessandro Vicentini¹

Affiliations

¹ Cardiac Intensive Care Unit, Arrhythmia and Electrophysiology & Laboratory of Clinical & Experimental Cardiology, Fondazione IRCCS Policlinico San Matteo.
² Department of Molecular Medicine, Cardiology Unit, University of Pavia.
³ Division of Cardiology, Fondazione IRCCS Policlinico San Matteo.
⁴ Division of Infectious Disease.
⁵ Department of Internal Medicine.
⁶ Division of Respiratory Diseases, Fondazione IRCCS Policlinico San Matteo & University of Pavia, Italy.
⁷ Emergency Department, Fondazione IRCCS Policlinico San Matteo.
⁸ Department of Clinical-Surgical, Diagnostic & Pediatric Sciences, Unit of Anesthesia & Intensive Care, University of Pavia.
⁹ Anaesthesia and Intensive Care, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Enrico Baldi et al. J Cardiovasc Med (Hagerstown). 2022.

. 2022 Jan 1;23(1):e21-e23.

doi: 10.2459/JCM.0000000000001238.

¹ Cardiac Intensive Care Unit, Arrhythmia and Electrophysiology & Laboratory of Clinical & Experimental Cardiology, Fondazione IRCCS Policlinico San Matteo.
² Department of Molecular Medicine, Cardiology Unit, University of Pavia.
³ Division of Cardiology, Fondazione IRCCS Policlinico San Matteo.
⁴ Division of Infectious Disease.
⁵ Department of Internal Medicine.
⁶ Division of Respiratory Diseases, Fondazione IRCCS Policlinico San Matteo & University of Pavia, Italy.
⁷ Emergency Department, Fondazione IRCCS Policlinico San Matteo.
⁸ Department of Clinical-Surgical, Diagnostic & Pediatric Sciences, Unit of Anesthesia & Intensive Care, University of Pavia.
⁹ Anaesthesia and Intensive Care, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

No abstract available

References

1. Zhu N, Zhang D, Wang W, et al. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382:727–733.
1. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial. Int J Antimicrob Agents 2020; 56:105949.
1. Fiolet T, Guihur A, Rebeaud ME, Mulot M, Peiffer-Smadja N, Mahamat-Saleh Y. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clin Microbiol Infect 2020; 27:19–27.
1. Lane JCE, Weaver J, Kostka K, et al. OHDSI-COVID-19 consortium. Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatol 2020; 2:e698–e711.
1. Saleh M, Gabriels J, Chang D, et al. The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection. Circ Arrhythmia Electrophysiol 2020; 18:e008662.